The year in review... November 28, 2018 - Coept
Post# of 30067
(Total Views: 1025)
Posted On: 10/31/2019 6:37:39 PM
The year in review...
November 28, 2018 - Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
This is now terminated:
"Amarantus and Coeptis Pharmaceuticals have mutually agreed to terminate the pending merger of Elto Pharma and Coeptis."
December 19, 2018 - The Company completed an exchange agreement with preferred shareholder Mr. Heng Fai Chan
- 99 shares of Series C stock, which will convert into 9.9% of Company common stock
- 9.9% of subsidiary Elto Pharma
- 9.9% of subsidiary Cutanogen Corporation
- 9.9% of subsidiary Breakthrough Diagnostics
February 28, 2019 - Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
May 28, 2019 - Engages Evolution Venture Partners (www.evovp.com), a crossover-focused biopharmaceutical advisory and investment firm
GC: "It has become crystal clear that focusing on generating free cash-flow will give Amarantus and its various stakeholders the best opportunity to unlock the tremendous value inherent in the Amarantus subsidiary portfolio."
June 25, 2019 - Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
Dead?
September 9th, 2019, the Company entered into a financing transaction with EMA Financial whereby the Company issued to EMA a convertible promissory note with a face value of $500,000. The Note carries a 10% original issue discount and 12% interest
September 27, 2019 - Form 1-A - Offering Statement [Regulation A]:
October 24, 2019 - Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
Opportunity
- Therapeutic assets have received a total of over $150 million in research & development investment to date
- Two Phase 3-ready product candidates in the areas of neurology and severe burns
- Combined independent valuations of over $500 million
- Targeting market opportunities of over $35B annually
What Emerald Organic Growth, Inc. gets:
Worldwide, exclusive development and commercial rights (license) to
- Eltoprazine (90.1-100%?)
- Engineered skin substitute (ESS) (90.1-100%?)
- Mesencephalic astrocyte-derived neurotrophic factor (MANF)
- PhenoGuard (golden goose 100%)
What Emerald Organic Growth, Inc. doesn't get:
- Diagnostics side with Breakthrough & Todos Medical (15%)
- 32.4% common stock ownership in Avant Diagnostics, Inc.
What Amarantus gets:
- Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022
- Double digit royalties
- Passthrough royalties and milestones payments
Must be serious to include the goose
November 28, 2018 - Coeptis Pharma Enters into Agreement to Acquire Elto Pharma
This is now terminated:
"Amarantus and Coeptis Pharmaceuticals have mutually agreed to terminate the pending merger of Elto Pharma and Coeptis."
December 19, 2018 - The Company completed an exchange agreement with preferred shareholder Mr. Heng Fai Chan
- 99 shares of Series C stock, which will convert into 9.9% of Company common stock
- 9.9% of subsidiary Elto Pharma
- 9.9% of subsidiary Cutanogen Corporation
- 9.9% of subsidiary Breakthrough Diagnostics
February 28, 2019 - Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience
May 28, 2019 - Engages Evolution Venture Partners (www.evovp.com), a crossover-focused biopharmaceutical advisory and investment firm
GC: "It has become crystal clear that focusing on generating free cash-flow will give Amarantus and its various stakeholders the best opportunity to unlock the tremendous value inherent in the Amarantus subsidiary portfolio."
June 25, 2019 - Amarantus Enters into Letter of Intent with The Alchemists Kitchen to Establish Joint Venture for Research and Commercialization of Hemp and Herbal Smokables for Addiction Treatment Including Smoking Cessation
Dead?
September 9th, 2019, the Company entered into a financing transaction with EMA Financial whereby the Company issued to EMA a convertible promissory note with a face value of $500,000. The Note carries a 10% original issue discount and 12% interest
September 27, 2019 - Form 1-A - Offering Statement [Regulation A]:
October 24, 2019 - Amarantus Enters Into Agreement to License Diverse Therapeutics Portfolio to CBD-focused Emerald Organic Products
Opportunity
- Therapeutic assets have received a total of over $150 million in research & development investment to date
- Two Phase 3-ready product candidates in the areas of neurology and severe burns
- Combined independent valuations of over $500 million
- Targeting market opportunities of over $35B annually
What Emerald Organic Growth, Inc. gets:
Worldwide, exclusive development and commercial rights (license) to
- Eltoprazine (90.1-100%?)
- Engineered skin substitute (ESS) (90.1-100%?)
- Mesencephalic astrocyte-derived neurotrophic factor (MANF)
- PhenoGuard (golden goose 100%)
What Emerald Organic Growth, Inc. doesn't get:
- Diagnostics side with Breakthrough & Todos Medical (15%)
- 32.4% common stock ownership in Avant Diagnostics, Inc.
What Amarantus gets:
- Amarantus will receive Emerald Preferred Stock to be valued at a minimum of $100M in 2022
- Double digit royalties
- Passthrough royalties and milestones payments
Must be serious to include the goose
(6)
(0)